Motilal Oswal has upgraded Orobindo Pharma Limited to ‘Buy’ rating with a target price of Rs 1,360, highlighting the company’s promising development trajectory and strategic investment in several high-power segments. Brokerage highlighted the company’s efforts to increase continuous growth over the next few years.
Aurobindo Pharma is actively investing in various segments to ensure long -term development. The company is scaling the Pen-G project and is expected to contribute physically for profitability in FY26 and FY27. “Penicillin G project is scaling meaningfully, effectively curbing operating loss.”
In the US generic market, Aurobindo Pharma continued to strengthen its position by continuously adding limited competition products to its portfolio, said Motilal said. Brokerage said, “Aurobindo Pharma stands out to be the most diverse American generic portfolio, performing flexibility against pricing pressure,” Brokerage said.
(Tagstotranslet) Aurobindo Pharma Limited.
